tiprankstipranks
Trending News
More News >
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
US Market
Advertisement

Rapport Therapeutics, Inc. (RAPP) Drug Pipeline

Compare
99 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Rap-219
Epilepsy, Focal Onset Seizure, Focal Epilepsy, Focal Seizure, Refractory Focal Epilepsy, Seizure
Phase II
Not Yet Recruiting
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
Oct 08, 2025
Rap-219
Bipolar 1 Disorder
Phase II
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
May 30, 2025
Rap-219
Focal Onset Seizures
Phase II
Active Not Recruiting
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
Apr 17, 2024

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Rapport Therapeutics, Inc. (RAPP) have in its pipeline
      RAPP is currently developing the following drugs: Rap-219, Rap-219, Rap-219. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis